Inventor · disambiguated record
Steven Stacker
Also filed as: STACKER STEVEN · STACKER STEVEN A · STACKER STEVEN ALAN
22 granted patents·18 pending applications·514 citations·filing 1993–2014
96Inventor score
Top patents by PatentIndex Score
40 records- 0196US6235713B1Vascular endothelial growth factor-D (VEGF-D) polypeptidesLUDWIG INST CANCER RES·Filed 1997·Granted May 22, 2001·113 cites·16 claims
- 0294US7122654B2Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of useUNIV HELSINKI LICENSING·Filed 2002·Granted Oct 17, 2006·33 cites·1 claims
- 0394US6689352B2Method for activating only the vascular endothelial growth factor receptor-3 and uses thereofLUDWIG INST CANCER RES·Filed 2001·Granted Feb 10, 2004·55 cites·10 claims
- 0494US6383484B1Antibodies to truncated VEGF-D and thereofLUDWIG INST CANCER RES·Filed 1999·Granted May 7, 2002·115 cites·22 claims
- 0593US7785803B2Antibody diagnostic kits and methods of useVEGENICS LTD·Filed 2007·Granted Aug 31, 2010·14 cites·6 claims
- 0693US6689580B1Growth factorLUDWIG INST CANCER RES·Filed 1999·Granted Feb 10, 2004·59 cites·14 claims
- 0792US7410639B2Vascular endothelial growth factor D(VEGF-D) antibodies and methods of useVEGENICS LTD·Filed 2002·Granted Aug 12, 2008·25 cites·33 claims
- 0889US7928061B2Methods of using VEGF-D polypeptidesVEGENICS PTY LTD·Filed 2007·Granted Apr 19, 2011·6 cites·15 claims
- 0986US6730489B1Antibodies to truncated VEGF-D and uses thereofLUDWIG INST CANCER RES·Filed 2002·Granted May 4, 2004·20 cites·20 claims
- 1085US7871798B2Mammalian cells that express VEGF-D polypeptidesVEGENICS LTD·Filed 2007·Granted Jan 18, 2011·3 cites·13 claims
- 1184US8227410B2Methods of stimulating wound healing by administration of vascular endothelial growth factor D (VEGF-D)ACHEN MARC G·Filed 2011·Granted Jul 24, 2012·4 cites·12 claims
- 1284US7097986B2Antibodies to truncated VEGF-D and uses thereofLUDWIG INST CANCER RES·Filed 2004·Granted Aug 29, 2006·15 cites·6 claims
- 1380US7045133B2VEGF-D/VEGF-C/VEGF peptidomimetic inhibitorLUDWIG INST CANCER RES·Filed 2001·Granted May 16, 2006·16 cites·33 claims
- 1474US7846437B2Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using sameVEGENICS LTD·Filed 2008·Granted Dec 7, 2010·1 cites·4 claims
- 1572US7534572B2Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissueVEGENICS LTD·Filed 2003·Granted May 19, 2009·8 cites·11 claims
- 1668US2011059890A1Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomasVEGENICS LTD·Filed 2009·Application pending·0 cites
- 1766US2008145366A1Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of useLICENTIA LTD·Filed 2007·Application pending·0 cites
- 1863US2006177428A1Vascular endothelial growth factor D (VEGF-D) antibodies and vectors, and methods of useUNIV HELSINKI LICENSING·Filed 2005·Application pending·0 cites
- 1961US6541008B1Vascular endothelial growth factor-like protein from orf viruses binds and activates mammalian VEGF receptor-2, and uses thereofUNIV OTAGO·Filed 1999·Granted Apr 1, 2003·18 cites·17 claims
- 2060US2004175730A1Vascular endothelial growth factor D(VEGF-D) antibodies and vectors, and methods of useLUDWIG INST CANCER RES·Filed 2003·Application pending·0 cites
- 2159US8461109B2Method of enhancing the acceptance and/or healing of a skin graftACHEN MARC G·Filed 2012·Granted Jun 11, 2013·0 cites·3 claims
- 2258US7479270B2Methods and compositions for activating VEGF-D and VEGF-CVEGENICS LTD·Filed 2003·Granted Jan 20, 2009·0 cites·11 claims
- 2358US2011142839A1Treatment of pulmonary edemaVEGENICS LTD·Filed 2009·Application pending·0 cites
- 2454US2006024302A1Chimeric anti-VEGF-D antibodies and humanized anti-VEGF-D antibodies and methods of using sameLUDWIG INST CANCER RES·Filed 2005·Application pending·0 cites
- 2554US2011269146A1Expression Vectors and Cell Lines Expressing Vascular Endothelial Growth Factor D, and Method of Treating MelanomasVEGENICS LTD·Filed 2010·Application pending·0 cites
- 2651US7947472B2Expression vectors and cell lines expressing vascular endothelial growth factor DVEGENICS LTD·Filed 1998·Granted May 24, 2011·6 cites·8 claims
- 2750US2011189170A1Chimeric Anti-VEGF-D Antibodies and Humanized Anti-VEGF-D Antibodies and Methods of Using the SameVEGENICS LTD·Filed 2010·Application pending·0 cites
- 2847US2011305703A1Isolated vegf-c and vegf-d peptides and uses thereofACHEN MARC G·Filed 2009·Application pending·0 cites
- 2946US2007212390A1Protease-resistant forms of VEGF-D, method of making and method of useLUDWIG INST CANCER RES·Filed 2006·Application pending·0 cites
- 3046US2002102260A1Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissueFiled 2001·Application pending·0 cites
- 3145US2003228283A1Preventing secondary lymphedema with VEGF-D DNALUDWIG INST CANCER RES·Filed 2003·Application pending·0 cites
- 3242US9862776B2Antibodies against human RYK and uses thereforPETER MACCALLUM CANCER INST·Filed 2014·Granted Jan 9, 2018·0 cites·2 claims
- 3342US2003211101A1Vascular endothelial growth factor-like protein from ORF viruses binds and activates mammalian VEGF receptor-2, and uses thereofFiled 2003·Application pending·0 cites
- 3442US2007224194A1Methods for Inhibiting Angiogenesis and/or LymphangiogenesisLUDWIG INST CANCER RES·Filed 2006·Application pending·0 cites
- 3541US2005282233A1Multivalent antibody materials and methods for VEGF/PDGF family of growth factorsLICENTIA LTD·Filed 2005·Application pending·0 cites
- 3639US2001038842A1Methods for treating various cancers expressing vascular endothelial growth factor D, for screening for a neoplastic disease and for maintaining vascularization of tissueFiled 2001·Application pending·0 cites
- 3737US2005272664A1Methods for inhibiting angiogenesis and or lymphangiogenesisLUDWIG INST CANCER RES·Filed 2005·Application pending·0 cites
- 3835US6107472AReceptor-type tyrosine kinase-like moleculesLUDWIG INST CANCER RES·Filed 1993·Granted Aug 22, 2000·3 cites·12 claims
- 3932US2004115660A1Method of diagnosising abnormalities by screening for tyrosine kinase like molecules or their signalling mediatorsFiled 2001·Application pending·0 cites
- 4025US6218516B1Antibodies specific for the extracellular domain of NYK/flk-1 protein and uses thereofLUDWIG INST CANCER RES·Filed 1995·Granted Apr 17, 2001·0 cites·7 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →